153 related articles for article (PubMed ID: 32931706)
1. Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor.
Hutchinson I; McNally P
Ann Am Thorac Soc; 2021 Jan; 18(1):182-183. PubMed ID: 32931706
[No Abstract] [Full Text] [Related]
2. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
Munce D; Lim M; Akong K
Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
[TBL] [Abstract][Full Text] [Related]
3. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.
Mainz JG; Arnold C; Hentschel J; Tabori H
Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672
[No Abstract] [Full Text] [Related]
4. Energy Balance and Mechanisms of Weight Gain with Ivacaftor Treatment of Cystic Fibrosis Gating Mutations.
Stallings VA; Sainath N; Oberle M; Bertolaso C; Schall JI
J Pediatr; 2018 Oct; 201():229-237.e4. PubMed ID: 30029855
[TBL] [Abstract][Full Text] [Related]
5. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
Megalaa R; Gopalareddy V; Champion E; Goralski JL
Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
7. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
8. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
9. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
10. Ivacaftor for patients with cystic fibrosis.
Wainwright CE
Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
[TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
13. Sustained recovery of exocrine pancreatic function in a teenager with cystic fibrosis treated with ivacaftor.
Smith H; Rayment JH
Pediatr Pulmonol; 2020 Oct; 55(10):2493-2494. PubMed ID: 32678518
[No Abstract] [Full Text] [Related]
14. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
15. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
Dryden C; Wilkinson J; Young D; Brooker RJ;
Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
17. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
[No Abstract] [Full Text] [Related]
18. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
20. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
